NOTABLE LABS LTD (NTBL) Stock Price & Overview

NASDAQ:NTBL • IL0012002452

Current stock price

0.2479 USD
-0.09 (-27.68%)
At close:
0.2456 USD
0 (-0.93%)
After Hours:

The current stock price of NTBL is 0.2479 USD. Today NTBL is down by -27.68%. In the past month the price decreased by -45.4%. In the past year, price decreased by -90.85%.

NTBL Key Statistics

52-Week Range0.22 - 4.24
Current NTBL stock price positioned within its 52-week range.
1-Month Range0.22 - 0.6658
Current NTBL stock price positioned within its 1-month range.
Market Cap
2.395M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-6.91
Dividend Yield
N/A

NTBL Stock Performance

Today
-27.68%
1 Week
-7.78%
1 Month
-45.40%
3 Months
-60.34%
Longer-term
6 Months -74.31%
1 Year -90.85%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

NTBL Stock Chart

NOTABLE LABS LTD / NTBL Daily stock chart

NTBL Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to NTBL. When comparing the yearly performance of all stocks, NTBL is a bad performer in the overall market: 98.93% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NTBL Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to NTBL. Both the profitability and financial health of NTBL have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NTBL Earnings

On August 14, 2024 NTBL reported an EPS of -0.55 and a revenue of 2.00K. The company missed EPS expectations (-25.98% surprise).

Next Earnings DateNov 12, 2024
Last Earnings DateAug 14, 2024
PeriodQ2 / 2024
EPS Reported-$0.55
Revenue Reported2K
EPS Surprise -25.98%
Revenue Surprise %

NTBL Forecast & Estimates

8 analysts have analysed NTBL and the average price target is 9.18 USD. This implies a price increase of 3603.11% is expected in the next year compared to the current price of 0.2479.


Analysts
Analysts80
Price Target9.18 (3603.11%)
EPS Next Y-81.59%
Revenue Next YearN/A

NTBL Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

NTBL Financial Highlights

Over the last trailing twelve months NTBL reported a non-GAAP Earnings per Share(EPS) of -6.91. The EPS increased by 65.56% compared to the year before.


Income Statements
Revenue(TTM)313.00K
Net Income(TTM)-16.74M
Industry RankSector Rank
PM (TTM) N/A
ROA -152.09%
ROE -232.9%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%-41.52%
Sales Q2Q%N/A
EPS 1Y (TTM)65.56%
Revenue 1Y (TTM)-34.79%

NTBL Ownership

Ownership
Inst OwnersN/A
Shares9.66M
Float6.27M
Ins Owners16.5%
Short Float %N/A
Short RatioN/A

About NTBL

Company Profile

NTBL logo image Notable Labs Ltd. engages in the development of predictive medicines for patients with cancer. The company is headquartered in Foster City, California and currently employs 16 full-time employees. The company went IPO on 2014-09-30. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

Company Info

IPO: 2014-09-30

NOTABLE LABS LTD

320 Hatch Drive

Foster City CALIFORNIA US

Employees: 16

NTBL Company Website

Phone: 14158512410

NOTABLE LABS LTD / NTBL FAQ

What does NOTABLE LABS LTD do?

Notable Labs Ltd. engages in the development of predictive medicines for patients with cancer. The company is headquartered in Foster City, California and currently employs 16 full-time employees. The company went IPO on 2014-09-30. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.


What is the stock price of NOTABLE LABS LTD today?

The current stock price of NTBL is 0.2479 USD. The price decreased by -27.68% in the last trading session.


Does NOTABLE LABS LTD pay dividends?

NTBL does not pay a dividend.


What is the ChartMill rating of NOTABLE LABS LTD stock?

NTBL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the analyst forecast for NTBL stock?

8 analysts have analysed NTBL and the average price target is 9.18 USD. This implies a price increase of 3603.11% is expected in the next year compared to the current price of 0.2479.


What is the market capitalization of NTBL stock?

NOTABLE LABS LTD (NTBL) has a market capitalization of 2.39M USD. This makes NTBL a Nano Cap stock.


What is the ownership structure of NOTABLE LABS LTD (NTBL)?

You can find the ownership structure of NOTABLE LABS LTD (NTBL) on the Ownership tab.